Revenue segments as reported by the company.

Product revenue

Service and other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Goodwill Impairment

Restructuring costs

Intangible assets and other long-lived assets impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bionano Genomics

Bionano Genomics, Inc. is a life sciences instrumentation company, which focuses on the genome analysis space. The firm engages in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline cytogenetics. Its products include Saphyr, Bionano Chips, Bionano Prep Kits, and Bionano Data Solutions. The company was founded by Han Cao in January 2003 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bionano Genomics reports robust Q1 performance and strategic growth plans

Bionano Genomics demonstrated strong revenue growth and operational progress in Q1 2024.
While facing short-term revenue challenges, the company's strategic initiatives and product advancements position it for long-term success.
Efforts to reduce expenses and expand the customer base underscore Bionano's commitment to sustainable growth.

Bionano Genomics reports Q2 revenue decline, focuses on growth strategies

Bionano Genomics faced revenue decline in Q2 2024, attributed to discontinued services and challenges in China.
Despite operational streamlining efforts, the company aims to drive growth through product advancements and partnerships.
Lowered revenue guidance underscores the need for strategic adjustments to navigate market challenges and optimize performance.

Bionano Genomics reports Q3 revenue decline but shows cost efficiency

Bionano Genomics showcased operational improvements with cost reductions and growth in key metrics despite a revenue decline.
The company's focus on expense reduction, revenue growth, and profitability sets a strategic direction for future success.
Challenges persist in revenue generation and cost management, but opportunities in technology adoption and market expansion are evident.
Overall, Bionano Genomics aims to balance financial stability with growth initiatives to drive long-term value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CBAK Energy Technology Inc

Castor Maritime Inc

Add these penny stocks to your January 2022 watchlist The post Best Penny Stocks to Buy in January 2022? 3 to Watch Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks to Buy in January 2022? 3 to Watch Next Week

SAN DIEGO, Dec. 29, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of the leading software solutions for visualization, interpretation and reporting of genomic data, today announced that it has completed the first prototype for its next single molecule imaging system for OGM. The prototype is being used to integrate and test the key engineering designs of a new instrument and consumable intended to meet the needs of high volume users. The commercial system based on this prototype is expected to be released in the first half of 2023.

Bionano Announces Prototype for its Next Single Molecule Imaging System for OGM

The critics of Bionano are greatly underestimating the vast potential of Saphyr and of BNGO stock for long-term investors. The post The Critics Are Wrong About Bionano Stock appeared first on InvestorPlace.

The Critics Are Wrong About Bionano Stock

SAN DIEGO, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of the leading software solutions for visualization, interpretation and reporting of genomic data, today announced that University Hospitals Leuven in Belgium, after previously receiving its accreditation from the Belgian Accreditation Body (BELAC) for using OGM in analysis of acute lymphoblastic leukemia (ALL), is expanding its BELAC-accredited menu to include acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and facioscapulohumeral muscular dystrophy (FSHD).

University Hospitals Leuven in Belgium Outlines their Menu Expansion Plans for Optical Genome Mapping as One of their Primary Analyses in Leukemias & Lymphomas and Genetic Disease

SAN DIEGO, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of the leading software solutions for visualization, interpretation and reporting of genomic data, today announced the appointment of Vincent Wong, JD, MBA, to its board of directors.

Bionano Genomics Appoints Vince Wong to its Board of Directors

If BNGO stock reaches Oppenheimer's price target, investors are looking at a return of more than 300%, plus long-term growth potential. The post This Analyst's Saphyr Calculations Suggest Buying Bionano While It's Down appeared first on InvestorPlace.

This Analyst's Saphyr Calculations Suggest Buying Bionano While It's Down

Investors need to pay close attention to Bionano (BNGO) stock based on the movements in the options market lately.

Do Options Traders Know Something About Bionano (BNGO) Stock We Don't?

Bionano sells a $150,000 machine called Saphyr that does genetic mapping. It's a solid device, but its future remains in the future, as do BNGO stock fortunes.

Bionano Genomics Proves Not Everything Genetic is Gold

BioCryst Pharmaceuticals

NRX Pharmaceuticals

Bionano Genomics, BioCryst Pharmaceuticals, and NRx Pharmaceuticals all have the potential to make their early shareholders rich.

3 Incredibly Cheap Growth Stocks That Could Make You a Millionaire

BNGO stock is breaking down following the latest earnings report, and there are no major catalysts to push shares up in the short term. The post Wait for Bionano Stock to Fall Further Before Buying appeared first on InvestorPlace.

Wait for Bionano Stock to Fall Further Before Buying

BNGO stock beats analyst forecasts yet again. Flush with cash and with Saphyr installations rising, this stock remains a high potential play.

Bionano's Is on Track for Growth Thanks to Saphyr

Bionano's acquisition of a software company makes Saphyr more attractive, and studies should result in insurers reimbursing those who use the system. BNGO stock is a buy.

With Progress on Multiple Fronts, Bionano Genomics Stock Is Great Buy Here

Bionano Genomics, Inc. (BNGO) CEO Erik Holmlin on Q3 2021 Results - Earnings Call Transcript

SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that, in accordance with Nasdaq Listing Rule 5635(c)(4), the Compensation Committee of its Board of Directors granted the following non-qualified stock options pursuant to the company's 2020 Inducement Plan to new employees as an inducement material to such employees entering into employment with Bionano:

Bionano Genomics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

The stock price of BioNano Genomics Inc (NASDAQ: BNGO) increased by over 10% during intraday trading today. This is why it happened.

BNGO Stock: Why The Price Surged Today

Ocugen, Inc.

Bionano Genomics and Ocugen could both be gearing up for a healthy rally this month.

2 Best Biotech Stocks to Buy in November

SAN DIEGO, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Thursday, November 4, 2021 at 4:30 p.m. Eastern Time to report financial results for the third quarter ended September 30, 2021 and to highlight recent corporate progress.

Bionano Genomics to Report Third Quarter 2021 Financial Results and Host a Conference Call and Webcast on November 4, 2021

It may take time for it to potentially move back to its all-time high of $15.69 per share. But given that's nearly triple what it trades today, patience could pay off big with BNGO stock.

Bionano Genomics Is Still Set to Pay Off Big for Patient Investors

BNGO stock isn't a darling of the markets at the moment, but Bionano continues to advance its stature in the optical genome mapping niche. The post Bionano Genomics' Latest Software Business Acquisition Adds Immense Value appeared first on InvestorPlace.

Bionano Genomics' Latest Software Business Acquisition Adds Immense Value

BNGO stock is down 25% since the beginning of the year. But as the company begins to deliver consistent revenue, a prudent investment may be rewarded.

Bionano Genomics Stock Looks Ready to Reward Patient Investors

SAN DIEGO, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), developer of the Saphyr® system that uses optical genome mapping (OGM) for the detection and analysis of structural variants (SVs), today announced the American Society of Human Genetics (ASHG) conference lineup of customer posters and presentations featuring OGM. The customer posters and presentations span genetic disease applications including amyotrophic lateral sclerosis (ALS) and postnatal, as well as cancer research applications including pediatric brain tumors and myelodysplastic syndromes (MDS). The ASHG conference is being held virtually this year and runs from Monday, October 18, 2021 to Friday, October 22, 2021.

Bionano Genomics Announces American Society of Human Genetics Presentations Featuring Optical Genome Mapping for Genetic Disease and Cancer Research Applications

The stock price of BioNano Genomics Inc (NASDAQ: BNGO) increased by over 6% this past week. This is why it happened.

BNGO Stock: Why It Increased This Past Week

Bionano has just made a deal that will help it secure a spot among biotech companies riding the wave of the current boom. BNGO stock is up.

BNGO Stock: The Big Acquisition News Sending Bionano Genomics Soaring

SAN DIEGO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO) today announced that it has entered into a definitive agreement to acquire BioDiscovery, Inc., a leading software company with best-in-class solutions for analysis, interpretation and reporting of genomics data. The transaction is expected to accelerate and broaden Bionano's market leadership in digital cytogenetics and comprehensive genome analysis. As a result of the transaction, Soheil Shams, PhD, Founder and Chief Executive Officer of BioDiscovery, will join Bionano's leadership team as Chief Informatics Officer.

Bionano Genomics to Acquire BioDiscovery, Furthering Bionano's Vision of Creating the Most Comprehensive Variant Analysis Platform in Genomics

Off and on the price chart, Bionano Genomics could be the next big thing in genomics with multiple catalysts for BNGO stock. The post Groundbreaking Tech Makes Bionano Genomics Look Better Than Ever appeared first on InvestorPlace.

News for Bionano Genomics Stock (BNGO)